That's a stretch. For one, allergy season's about over. You can talk all you want about indoor allergens, but bank is made in this sector on allergy season sales. And INNV still has to sell Fluticare to someone other than excited shareholders, so I'll believe that the 4th quarter will be the strongest Q when I see it, which won't be until the end of March. Even if they sell all of it in Dec, the 4Q's SG&A exponential growth to buy 1st order and launch the marketing will temper the rev growth. They have a ways to go and a lot to prove on the marketing side of this.
Market Data 
Markets 
AI
